🔗 Share this article

Given that the United States proceeds with historic revisions to its vaccination guidelines, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by questioning coronavirus vaccines during the pandemic and has focused upon alleged deaths following Covid vaccination in her brief time at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Vaccine Program

Agency leaders were set to reveal major revisions to the pediatric vaccine schedule earlier this month, aligning the US with the Danish vaccine program, according to reports – a major change that would place the US out of alignment with a large portion of the world with insufficient data for improved outcomes. The planned update has been delayed until the next year.

In place of the top vaccines chief, Dr. Høeg is set to address the audience at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to head the office this year.

Consolidating Power at the FDA

The acting appointment might represent a strengthened alliance between the drug and vaccine branches as Høeg and Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon rolling back long-standing immunizations at the FDA.

Høeg has often pushed for ending some pediatric vaccine recommendations in the US to become more like Denmark's approach, a country with universal health coverage and a number of inhabitants about the population of Wisconsin’s.

So far comments, she has continued to focus on vaccines – typically the purview of Dr. Prasad, chief of the FDA’s vaccine center – rather than pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has no apparent background in drug development, approval processes or management, which has been customary for previous heads of the CBER. She has worked at the FDA as a key advisor to the agency head and CBER since spring.

“She appears not to have the requisite experience” for leading the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in running a major agency. She has no expertise in pharmaceutical oversight.”

Previous directors of the center would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

CDER has an vast workload at the agency, she emphasized.

“Many people just zeroes in on the new drug program, but the off-patent medication office approves a multitude of generic drugs. There’s a biosimilars program, over-the-counter program and more, and all of those have to be supervised,” Dr. Woodcock noted. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a significant leadership element to the job, which supervises in excess of 5,000 staff members. “It is a massive leadership role, if you perform it correctly,” Woodcock said.

Response and Disputed Programs

Regarding concerns about Dr. Høeg's fitness for the role and whether this assignment signifies increased cooperation among regulatory chiefs on vaccines, a spokesperson responded that the “inquiries stem from inaccurate assumptions”.

“Her resume is consistent with the responsibilities of her position,” the representative explained, citing the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial expedited medication authorization process that reportedly concerned her former heads. “By what process are these drugs being chosen for this fast-track system? Who takes the calls?” Dr. Howard said. “There is a lot of secrecy occurring at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards less stringent regulations of all drugs, except for vaccines.”

Documented History on Vaccines

Regarding vaccines, Høeg has a clearer, if troubling, track record, critics have noted. She released a study using unconfirmed crowd-sourced reports to determine the frequency of heart inflammation following COVID-19 immunization. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are riskier than they are.

Among her “desired changes” for the new administration included altering rules for new vaccines and halting “optional” immunizations, she said after the election on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of preventing young men from getting COVID-19 vaccines.

“She is an complete true believer who starts off with her conclusions and tailors the evidence to accommodate the science in a highly disingenuous, untruthful way,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|